108 related articles for article (PubMed ID: 22131108)
1. Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.
Lindblom P; Berg AL; Zhang H; Westerberg R; Tugwood J; Lundgren H; Marcusson-Ståhl M; Sjögren N; Blomgren B; Öhman P; Skånberg I; Evans J; Hellmold H
Toxicol Pathol; 2012; 40(1):18-32. PubMed ID: 22131108
[TBL] [Abstract][Full Text] [Related]
2. Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.
Hellmold H; Zhang H; Andersson U; Blomgren B; Holland T; Berg AL; Elebring M; Sjögren N; Bamberg K; Dahl B; Westerberg R; Dillner B; Tugwood J; Tugwood J; Roberts R; Lundholm E; Camejo G; Skånberg I; Evans J
Toxicol Sci; 2007 Jul; 98(1):63-74. PubMed ID: 17468185
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
[TBL] [Abstract][Full Text] [Related]
4. Proliferative and molecular effects of the dual PPARalpha/gamma agonist tesaglitazar in rat adipose tissues: relevance for induction of fibrosarcoma.
Glinghammar B; Berg AL; Bjurström S; Stockling K; Blomgren B; Westerberg R; Skånberg I; Hellmold H; Andersson U
Toxicol Pathol; 2011 Feb; 39(2):325-36. PubMed ID: 21270424
[TBL] [Abstract][Full Text] [Related]
5. Food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist.
Samuelsson S; Johansson S; Halldórsdóttir S; Stenhoff H; Ohman KP
J Clin Pharmacol; 2006 Sep; 46(9):1017-22. PubMed ID: 16920896
[TBL] [Abstract][Full Text] [Related]
6. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
7. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
Rogue A; Renaud MP; Claude N; Guillouzo A; Spire C
Toxicol Appl Pharmacol; 2011 Jul; 254(1):18-31. PubMed ID: 21515302
[TBL] [Abstract][Full Text] [Related]
8. [Peroxisome proliferator-activated receptor α/γ agonist tesaglitazar stabilizes atherosclerotic plaque in diabetic low density lipoprotein receptor knockout mice].
Zhang BC; Li XK; Che WL; Li WM; Hou L; Wei YD; Xu YW
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Feb; 41(2):143-9. PubMed ID: 23710746
[TBL] [Abstract][Full Text] [Related]
9. Tesaglitazar.
Kamber N; Davis TM
IDrugs; 2005 Nov; 8(11):927-35. PubMed ID: 16254788
[TBL] [Abstract][Full Text] [Related]
10.
Osinski V; Bauknight DK; Dasa SSK; Harms MJ; Kroon T; Marshall MA; Garmey JC; Nguyen AT; Hartman J; Upadhye A; Srikakulapu P; Zhou A; O'Mahony G; Klibanov AL; Kelly KA; Boucher J; McNamara CA
Theranostics; 2020; 10(2):585-601. PubMed ID: 31903139
[TBL] [Abstract][Full Text] [Related]
11. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
Zadelaar AS; Boesten LS; Jukema JW; van Vlijmen BJ; Kooistra T; Emeis JJ; Lundholm E; Camejo G; Havekes LM
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2560-6. PubMed ID: 16931788
[TBL] [Abstract][Full Text] [Related]
12. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.
Fagerberg B; Schuster H; Birketvedt GS; Tonstad S; Ohman KP; Gause-Nilsson I;
Diab Vasc Dis Res; 2007 Sep; 4(3):174-80. PubMed ID: 17907107
[TBL] [Abstract][Full Text] [Related]
13. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
Schuster H; Fagerberg B; Edwards S; Halmos T; Lopatynski J; Stender S; Birketvedt GS; Tonstad S; Gause-Nilsson I; Halldórsdóttir S; Ohman KP;
Atherosclerosis; 2008 Mar; 197(1):355-62. PubMed ID: 17631296
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of direct and indirect effects of the PPARγ agonist troglitazone on mouse endothelial cell proliferation.
Kakiuchi-Kiyota S; Arnold LL; Yokohira M; Koza-Taylor P; Suzuki S; Varney M; Pennington KL; Cohen SM
Toxicol Pathol; 2011 Dec; 39(7):1032-45. PubMed ID: 21937740
[TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of Tetrafluoroethylene (CAS No. 116-14-3) in F344 Rats and B6C3F1 Mice (Inhalation Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 Apr; 450():1-321. PubMed ID: 12594525
[TBL] [Abstract][Full Text] [Related]
16. Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.
Oakes ND; Thalén P; Hultstrand T; Jacinto S; Camejo G; Wallin B; Ljung B
Am J Physiol Regul Integr Comp Physiol; 2005 Oct; 289(4):R938-46. PubMed ID: 16183630
[TBL] [Abstract][Full Text] [Related]
17. Toxicology and Carcinogenesis Studies of 5,5-Diphenylhydantoin (CAS No. 57-41-0) (Phenytoin) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Nov; 404():1-303. PubMed ID: 12621514
[TBL] [Abstract][Full Text] [Related]
18. PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice.
Blednov YA; Black M; Benavidez JM; Stamatakis EE; Harris RA
Alcohol Clin Exp Res; 2016 Mar; 40(3):553-62. PubMed ID: 26857685
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor alpha and alpha/gamma agonists do not cause impairment in renal function in the rat.
Ovcharenko E; Hansen MK; Goltsman I; Abu-Saleh N; Abassi Z; Walsh K; Miele G; Feuerstein GZ; Winaver J
Nephron Physiol; 2010; 115(3):p21-30. PubMed ID: 20460939
[TBL] [Abstract][Full Text] [Related]
20. Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats.
Liao J; Soltani Z; Ebenezer P; Isidro-Carrión AA; Zhang R; Asghar A; Aguilar E; Francis J; Hu X; Ferder L; Reisin E
Nephron Exp Nephrol; 2010; 114(2):e61-8. PubMed ID: 19887847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
